Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:07:21.690Z.
Calculation as of: 2026-10-06T20:07:21.690Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23bdec7124bcf20b562f8235598f93689ea1cbdfcf2aa7384f68a4c8921eaa93
PE RATIO
N/A
Market Cap
$8.67B
PE Ratio
N/A
TTM Avg
41.90
3Y Avg
41.90
5Y Avg
41.90
Market Cap
$8.92B
PE Ratio
134.17
TTM Avg
133.81
3Y Avg
61.10
5Y Avg
61.10
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.72B | N/A | N/A | N/A | N/A |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | N/A | 41.90 | 41.90 | 41.90 |
| Bruker Corporation (BRKRP)vs › | $8.91B | N/A | 552.62 | 552.62 | 552.62 |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.92B | 134.17 | 133.81 | 61.10 | 61.10 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 23.10 | 22.16 | 45.57 | 45.57 |
| Bruker Corporation (BRKR)vs › | $9.21B | N/A | 54.08 | 39.03 | 41.91 |
| Insulet Corp. (PODD)vs › | $9.33B | 25.18 | 58.80 | 65.23 | 3594.22 |
| TG Therapeutics, Inc. (TGTX)vs › | $7.99B | 19.05 | 21.60 | 190.21 | 190.21 |
| Vaxcyte, Inc. (PCVX)vs › | $9.61B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$105.98
Forward EPS (Est.)
$-3.85
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
